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Preclinical characterization of DUOC-01, a cell therapy product 
derived from banked umbilical cord blood for use as an adjuvant 
to umbilical cord blood transplantation for treatment of inherited 
metabolic diseases
JOANNE KURTZBERG1, SUSAN BUNTZ1, TRACY GENTRY1, PAMELA NOELDNER1, APRIL 
OZAMIZ1, BENJAMIN RUSCHE1, ROBERT W. STORMS1, AMY WOLLISH1, DAVID A. 
WENGER2, and ANDREW E. BALBER1
1Robertson Clinical and Translational Cell Therapy Program, Duke Translational Medicine 
Institute, Duke University Medical Center, Durham, North Carolina, USA
2Lysosomal Diseases Testing Laboratory, Thomas Jefferson University, Philadelphia, 
Pennsylvania, USA
Abstract
Background aims—Cord blood (CB) transplantation slows neurodegeneration during certain 
inherited metabolic diseases. However, the number of donor cells in the brain of patients does not 
appear to be sufficient to provide benefit until several months after transplant. We developed the 
cell product DUOC-01 to provide therapeutic effects in the early post-transplant period.
Methods—DUOC-01 cultures initiated from banked CB units were characterized by use of time-
lapse photomicroscopy during the 21-day manufacturing process. Antigen expression was 
measured by means of flow cytometry and immunocytochemistry; transcripts for cytokines and 
enzymes by quantitative real-time polymerase chain reaction; activities of lysosomal enzymes by 
direct biochemical analysis; alloreactivity of DUOC-01 and of peripheral blood (PB) mononuclear 
cells (MNC) to DUOC-01 by mixed lymphocyte culture methods; and cytokine secretion by 
Bioplex assays.
Results—DUOC-01 cultures contained highly active, attached, motile, slowly proliferating cells 
that expressed common (cluster of differentiation [CD]11b, CD14 and Iba1), M1 type (CD16, 
inducible nitric oxide synthase), and M2-type (CD163, CD206) macrophage or microglia markers. 
Activities of 11 disease-relevant lysosomal enzymes in DUOC-01 products were similar to those 
of normal PB cells. All DUOC-01 products secreted interleukin (IL)-6 and IL-10. Accumulation 
of transforming growth factor-β, IL-1β, interferon-γ and TNF-α in supernatants was variable. 
IL-12, IL-2, IL-4, IL-5 and IL-13 were not detected at significant concentrations. 
Galactocerebrosidase, transforming growth factor-β and IL-10 transcripts were specifically 
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enriched in DUOC-01 relative to CB cells. PB MNCs proliferated and released cytokines in 
response to DUOC-01. DUOC-01 did not proliferate in response to mismatched MNC.
Conclusions—DUOC-01 has potential as an adjunctive cell therapy to myeloablative CB 
transplant for treatment of inherited metabolic diseases.
Keywords
cord blood; cytokines; lysosomal enzymes; macrophage; microglia; transplantation
Introduction
Allogeneic hematopoietic stem cell transplantation with bone marrow or banked unrelated 
umbilical cord blood (CB) [1,2] slows the progression of central nervous system (CNS) 
damage associated with several inherited metabolic diseases (IMDs). In this treatment 
setting, cells derived from the donor eventually provide functional enzyme missing to the 
transplant recipients to cross-correct inherited enzyme deficiency [3,4]. Neurological 
symptoms usually stabilize 3 to 6 months after transplant, which suggests that brain 
engraftment reaches a therapeutic threshold during this period. Until this occurs, ongoing 
disease-associated CNS damage progresses [5]. To address this barrier to success of 
transplantation therapy, we developed DUOC-01, an adjunctive cell therapy product derived 
and manufactured ex vivo from donor CB. DUOC-01 is intended to be delivered 
intrathecally after systemic transplantation and after engraftment of donor cells as a bridging 
therapy to provide functional enzyme and perhaps other beneficial products to the brain in 
the early post-transplant period. DUOC-01 is a more than minimally manipulated cell 
product manufactured under current Good Manufacturing Practice (cGMP) from the 20% 
compartment of the systemically transplanted, 80% fraction of the same donor CB unit. In 
this report, we present data related to the identity, composition, immunogenicity and 
inflammatory potential of DUOC-01 cell products. Information concerning survival and 
biodistribution of DUOC-01 after intrathecal administration and the activity of DUOC-01 in 
treating demyelination in immune incompetent mice will be presented elsewhere. An 
investigational new drug application including this information has been reviewed by the US 
Food and Drug Administration, and a phase 1 trial (NCT02254863) exploring the safety and 
feasibility of the use of DUOC-01 in the clinical setting of allogeneic CB transplantation for 
IMD is currently enrolling subjects.
Methods
Material from human donors
All CB units (CBUs) and peripheral blood (PB) mononuclear cell fractions (MNC) were 
obtained from donors who had given informed consent for samples to be used for research 
purposes under local institutional review board–approved protocols.
Manufacturing DUOC-01
Cell products were manufactured in the Robertson Cell and Translational Cell Therapy 
cGMP facility from volume-reduced, red cell–depleted, and MNC-enriched cryopreserved 
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CBUs (Carolinas Cord Blood Bank) through the use of validated standard operating 
procedures. All reagents were qualified for clinical use on the basis of manufacturing history 
files, certificates of analysis and testing for viruses, endotoxin and sterility. The 20% volume 
fraction detached from a single CBU was used to produce a single DUOC-01 cell product; 
we refer to a manufacturing lot as a cell product manufactured from a single CBU 
throughout this report. A flow chart outlining the manufacturing process is presented in 
Supplementary Figure 1. Cells were cultured by use of the method of Tracy et al. [6] with 
two modifications. First, because contaminating red cells interfere with the development of 
DUOC-01 cells in culture [6], additional red cell depletion was carried out with the use of 
immunomagnetic beads coated with anti-glycophorin A antibody as previously described 
[7]. Second, during cultivation, the concentrations of platelet-derived growth factor (5 ng/
mL), neurotrophin-3 (1 ng/mL) and vascular endothelial growth factor (10 ng/mL) used 
were lower and of triiodothyronine (30 ng/mL) was higher than in the published protocol. 
On day 21, adherent cells were harvested with the use of trypsin and ethylenediaminetetra-
acetic acid followed by scraping and were washed in appropriate excipients for further 
studies.
Imaging of cells in culture during DUOC-01 manufacturing process
Glass-bottomed, 35-mm culture dishes (MatTek Corporation) were seeded with 4.75 × 106 
cells in 3 mL of growth medium through the use of standard manufacturing protocols and 
incubated for 4 days. On culture day 4, the dishes were fitted into the incubator of an 
Olympus VivaView FL incubator microscope. Transmitted differential interference contrast 
images of nine positions in each dish were captured with the use of a ×20 objective every 10 
or 30 min during the 21-day manufacturing cycle. Images were analyzed and video clips 
were created with the use of MetaMorph Automation and Image Analysis Software.
Antibodies and isotype controls
Unless noted, all reagents were derived from mice. For flow cytometry, anti–cluster of 
differentiation (CD)3 Alexa Fluor 488, anti-CD14 Alexa Fluor 488, anti-CD11b-PE, anti-
CD45-PECy7, anti-CD45-allophycocyanin (APC) and isotype controls immunoglobulin 
(Ig)G1 Alexa Fluor 488, IgG2a Alexa Fluor 488, and IgG2a-PE and IgG1 PECy7 were 
purchased from Becton Dickenson; mouse anti-human CD45 Alexa Fluor 488 and mouse 
anti-human CD45 Alexa Fluor 647 from AbDSerotec; anti-A2B5-APC and isotype control 
IgM APC from Miltenyi; and anti-O1 Alexa Fluor 647 and isotype control IgM Alexa Fluor 
660 from eBioscience.
Antibodies used for immunocytochemistry were purchased from eBioscience (anti-CD11b, 
anti-Ki67-Alexa Fluor 488, IgG1 Alexa Fluor 488), Abcam (rabbit anti–human leukocyte 
antigen [HLA]-DR, anti-CD14, rabbit monoclonal anti-CD16, rabbit anti-CD206, rabbit 
anti–inducible nitric oxide synthase (iNOS), goat anti-Iba1, rabbit IgG isotype and IgG2bk 
isotype), Pierce (anti-CD163) and Molecular Probes (donkey anti-mouse IgG and donkey 
anti-rabbit IgG Alexa Fluor 488 or 568).
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Flow cytometric analysis
DUOC-01 cell products were incubated for 15 min at 4°C in appropriate combinations of 
directly conjugated monoclonal antibodies and viability dyes, washed with phosphate-
buffered saline (PBS)/1% human serum albumen and analyzed by use of multiparameter 
flow cytometry. Side- and forward-scatter gates were set to exclude small debris, and 
viability dyes were used to exclude dead cells.
Immunocytochemistry
Cells (900,000 in 700-μL medium/well) were seeded in four-well chamber slides (Lab-Tek 
II CC2) and cultured according to standard protocol. On culture day 21, medium was 
removed by aspiration, the cells briefly washed in 1 mL of PBS, fixed by addition of 4% 
paraformaldehyde in PBS for 20 min, washed twice with PBS and stored in PBS at 4°C until 
staining. Cells were then permeabilized and blocked with 2% bovine serum albumin (BSA)–
0.1% Triton-X100 in PBS and incubated with primary antibody in 2% BSA in PBS. Both 
steps were carried out overnight at 4C°. The cells were then washed three times in PBS for 5 
min, stained with fluorochrome-labeled secondary antibody in 2% BSA in PBS for 2 h at 
room temperature, washed once in PBS for 5 min, incubated in 4′, 6-diamidino-2-
phenylindole (DAPI) at 1 μg/mL in PBS for 5 min to label cell nuclei, washed two more 
times with PBS and coverslip-mounted with Vectashield mounting medium.
For staining of cell proliferation, 5-bromo-2′-deoxyuridine (BrdU) was added to the cell 
culture at 10 μmol/L for 21 h and the cells were fixed and stained with the use of the anti-
BrdU immunohistochemistry kit (Abcam).
Apoptosis was measured with the use of the DeadEnd Fluorometric TUNEL System 
(Promega). Positive controls were prepared by incubating slides with benzoase (1 μL/mL 
PBS) for 10 min at room temperature.
Fluorescent and bright-field images were obtained with the use of a Zeiss Axio Imager 
microscope and analyzed with the use of MetaMorph software.
Secretion of lysosomal enzymes
Five lots of DUOC-01 product were manufactured at Duke. On day 21, flasks containing the 
cell product were filled with culture medium, placed on ice packs and shipped overnight to 
the Lysosomal Diseases Testing Laboratory at Thomas Jefferson University in Philadelphia, 
Pennsylvania. At Jefferson, cells were removed from plates with the use of trypsin, and the 
specific activity of 11 lysosomal enzymes was measured as described by Wenger and 
Williams [4].
Accumulation of cytokines in culture medium
Cytokine concentrations in culture supernatants from DUOC-01 products manufactured 
under cGMP conditions and from DUOC-01 cells that were exposed to inflammatory stimuli 
in vitro were measured by means of antibody capture immunoassay with fluorescence 
reporters with the use of the Bio Rad Bioplex 200 instrument. Assays for 10 human pro- and 
anti-inflammatory cytokines [interleukin (IL)-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12(p70), 
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IL-13, tumor necrosis factor (TNF)-α and interferon (IFN)-γ] were multiplexes in each well 
of a Bio Rad Precision Pro plate (No. 171-A1001P). TGF-β content of supernatants was 
measured with the use of the Bio-Plex Pro TGF-β1 Set (Biorad No. 171-V4001M). Cytokine 
standards provided by the manufacturer were diluted in uninoculated tissue culture medium 
to construct standard curves, and the concentration of each cytokine in the supernatants was 
calculated.
Quantitative real-time polymerase chain reaction (QRT-PCR) was used to measure levels of 
transcripts for transforming growth factor (TGF)-β, galactocerebrosidase (GALC), IL-10, 
TNF-α and IFN-γ in cells on days 1 and 21 of the manufacturing process. RNA was isolated 
from DUOC-01 cells with the use of a PureLink RNA Mini Kit (Life Technologies), 
followed by DNase treatment (Life Technologies). Complementary DNA (cDNA) was 
synthesized from 2 μg of total RNA with the use of the SuperScript Vilo cDNA Synthesis 
Kit (Life Technologies). QRT-PCR was performed with the use of Taqman primer and probe 
sets run on a Biorad CFX96 Real-Time System. All values are normalized to glyceraldehyde 
3-phosphate dehydrogenase expression.
Reactivity in mixed lymphocyte cultures
PB was drawn from healthy donors into heparinized tubes and centrifuged over Ficoll to 
yield MNC fractions. Freshly prepared PB MNCs from individual donors or frozen pooled 
PB MNCs from multiple donors were used in different experiments. Standard methods were 
used for one-way mixed lymphocyte culture (MLC) reactions in which stimulator cells were 
treated with mitomycin c before responder cells were added [8]. Cells were washed in PBS 
and cultured in Roswell Park Memorial Institute 1640 tissue culture medium containing 
20% fetal calf serum. To assay cytokines released from cells cultured in MLC conditions, 
supernatants were removed from MLC on day 6 just before pulsing with titrated thymidine, 
stored at −80°C and then were assayed for the presence of human IL-2, IL-4, IL-10, TNF-α 
and IFN-γ with the use of BioPlex Product No. M50000005V, Human Cytokine Group 1, 5-
plex custom assay. Standards containing known concentrations of each cytokine were 
diluted in culture medium to construct standard curves and calculate cytokine 
concentrations.
Results
General aspects of manufacturing process
Cultures initiated with the 20% fraction of frozen, banked CBUs, generally containing a 
heterogeneous populations of approximately 2 × 108 predominantly mature blood and 
hematopoietic cells, yielded 3.05 × 106 ± 1.63 × 106 (mean ± standard deviation [SD], range 
= 0.52–7.2 × 106, n = 14 total DUOC-01 cells after 21 days of manufacturing. Viability of 
DUOC-01 cells after harvest measured by trypan blue was 83% 9.9% (mean ± SD, n = 14).
Morphology of cells in DUOC-01 cultures
Figure 1 shows the range of morphologies present in the DUOC-01 cell product. Cultures 
included long, bipolar, phase-dense cells with radial processes (single broad arrow in Figure 
1) resembling the “oligodendrocyte-like cells” described by Tracy et al. [6,9]. Very large, 
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flat, vesiculated cells (double broad arrows in Figure 1) as large as 285 μm in diameter were 
common. Finally, highly refractive, small cells (thin arrow in Figure 1) were abundant. All 
cells adhered tightly to the plastic flasks. All three types of cells can be seen in the images 
shown by Tracy et al. [6,9].
We used immunocytochemistry of cells cultured on glass slides to study cell proliferation 
and apoptosis with the use of BrdU, Ki67 and the TUNEL assay. Cells were fixed in situ and 
not exposed to trypsin. The growth properties and morphologies of cells in slide cultures 
were similar to those grown under standard conditions in plastic flasks. BrdU and Ki67 
staining of cells revealed that all three types of cells could proliferate during the period just 
before harvesting and confirmed that the large, flat cells were often multinucleated (Figure 
2A–C). Apoptotic cells were not detected in slide cultures at the time of harvest (not shown).
To analyze relationships among the morphological types, we established glass slide cultures 
in a photomicroscope chamber and photographed defined fields of the cultures every 5, 10 or 
30 min in two experiments. Figure 3 illustrates some of the morphological changes that 
occur in the cultures. The most important finding that emerged from analysis of these videos 
was that the morphological variants in DUOC-01 interconvert into one another. We observed 
large vesicular cells detaching from the surface, rounding up and becoming actively motile 
refractile cells. We also saw the actively motile, round refractile cells adhering to the surface 
and spreading out to become large cells or small, very motile cells of 27 to 54 μm in size that 
extended and retracted small, stellate processes. Those cells migrated up to 2 μm/min, 
frequently rounded up and appeared to divide.
Composition of DUOC-01 products
We used flow cytometry and immunocytochemistry to examine the lineage phenotype and 
characterize the composition of DUOC-01. Figure 4 shows representative flow analysis, and 
Table I shows the results for the surface antigens evaluated by flow cytometry. We were 
particularly concerned with removing potentially alloreactive T cells during manufacturing, 
and flow analysis showed that CD3+ cells were not detected in cell products. Almost all 
DUOC-01 cells expressed CD45, and most cells expressed CD11b and/or CD14 
characteristic of macrophage and microglia.
We also used immunochemistry to explore expression of other markers in this lineage. 
Figure 5 shows that all the morphological types in 21-day DUOC-01 cultures grown on 
slides expressed macrophage/monocyte markers CD11b, CD14, HLA-DR, CD16, CD206, 
CD163 and iNOS.
Lysosomal enzyme activity
To determine if DUOC-01 could be a potential source of enzyme to cross-correct secreted 
enzyme deficiencies in patients with IMDs, activities of 11 lysosomal enzymes were 
measured in sonicates of cell products. Significant and normal levels of activities of all 11 
lysosomal enzymes were readily detected in all five lots of DUOC-01 analyzed (Table II). 
For each enzyme, the specific activity varied over a range similar to the range 
characteristically observed in blood cells derived from individuals without enzyme 
deficiencies.
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Cytokine secretion by DUOC-01
The concentration of cytokines in the culture medium of eight lots of DUOC-01 at the time 
the cells were harvested was measured with the use of Bioplex analysis. IL-4, IL-5 and 
IL-13 were not detected in any lots. Table III shows the concentrations of the other measured 
cytokines in each supernatant; these values are normalized to account for the number of cells 
present in each batch at the time of harvest. IL-1b and IL-12p70 were each only detected in 
one batch, both at very low levels. Only two cytokines in the panel, IL-6 and IL-10, were 
detected at appreciable concentrations in all eight batches. TGF-β was detected in harvest 
supernatants from seven of eight manufacturing lots. Three of eight lots produced relatively 
high concentrations of INF-γ, four lots produced low levels and no IFN-γ was detected in the 
medium of one lot. TNF-α and IL-2 were detected at very low levels.
Changes in cytokine secretion by DUOC-01 in response to inflammatory stimuli
Table IV shows the concentration of cytokines that accumulated in culture supernatants from 
replated DUOC-01 cells maintained in culture for 72 h without any added inflammatory 
stimulus. We did not obtain consistent evidence for TGF-β secretion with the use of this 
protocol. IL-6 and IL-10 were the only cytokines detected in unstimulated cultures. Thus, 
these cells continued to secrete these two cytokines after replating. Stimulation with TNF-α 
induced accumulation of all the cytokines in the panel except Il-13, but the levels of all 
cytokines besides IL-6 and IL-10 remained low after treatment with either 0.5 or 1.0 μg of 
TNF-α. IL-6 accumulation was increased 22.1- and 41.5-fold by 0.5 and 1.00 μg of TNF-α, 
respectively. IL-10 accumulation was enhanced 70.0- and 57.6-fold by 0.5 and 1.00 μg of 
TNF-α, respectively. Thus, IL-10 accumulation was stimulated more than was IL-6 at the 
concentrations of TNF-α used. Stimulation with 10 μg/mL of IFN-γ induced significant 
increases in accumulation of all the other nine cytokines in the panel. IFN-γ stimulated a 
19.8-fold increase in IL-6 accumulation and a 28.3-fold increase in IL-10 accumulation. 
Phorbol 12-myristate 13-acetate (PMA) treatment induced a slight increase in IL-1β 
accumulation, downregulated IL-6 accumulation 0.49-fold and increased IL-10 
accumulation 2.6-fold. Thus, all inflammatory stimuli stimulated IL-10 accumulation more 
strongly than IL-6 accumulation. We did not obtain consistent changes of TGF-β 
accumulation with these lots of DUOC-01 in this protocol.
Changes in messenger RNA levels for selected genes during manufacturing
We analyzed eight DUOC-01 cell products harvested at the end of the 21-day manufacturing 
period for expression of transcripts for selected gene products. The relative levels of 
expression (mean amplification cycle), from most to least abundant, of these gene products 
were TGF-β (24.8), GALC (25.3), IL-10 (25.3), TNF-α (29.1), and IFN-γ (35.0). We also 
compared expression of these transcripts by DUOC-01 cells harvested at 21 days with 
expression by cells on the first day of culture. Expression of IL-10 (22.5 ± 13.8-fold, P < 
0.01) and GALC (4.4 ± 2.8-fold, P < 0.05) messenger RNA by DUOC-01 increased 
significantly (unpaired t-test with Welch’s correction) from day zero to harvest. Changes in 
abundance of the TNF-α (0.9 ± 1.1-fold), TGF-β (1.2 ± 0.8-fold) and IFN-γ (0.02 ± 0.05-
fold) transcripts during the culture period were not statistically significant.
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Alloreactions to and by DUOC-01
MLC experiments were performed to determine whether cells in DUOC-01 proliferate in 
response to allogeneic, pooled third-party MNCs and also whether DUOC-01 can stimulate 
proliferation of allogeneic MNCs in culture. DUOC-01 proliferated very poorly (average 
CPM of 190; n = 15) in response to autologous or allogeneic cells.
We refer to experiments in which DUOC-01 and MNCs were prepared from different bag 
compartments of the same CBUs as autologous experiments. The autologous experiments 
mirrored the clinical protocol in which DUOC-01 is manufactured from the same CBUs that 
the patient receives as a transplant donor and established background proliferation rates 
when CB MNCs and DUOC-01 products are matched. Column A in Table V shows, as 
expected, that titrated thymidine incorporation was low under these conditions.
We refer to experiments in which PB or CB MNC respond to DUOC-01 products made from 
a different CBU as allogeneic experiments. In five experiments, randomly mismatched 
peripheral blood MNC from individual donors proliferated between 9.9- and 52.5-fold more 
strongly than autologous CB MNCs derived from the same CBU used to make the DUOC 
cell product (Table V, Column B). Thus, DUOC-01 can be recognized by alloreactive cells 
in mismatched PB MNC populations. We also measured proliferation of CB MNC in 
response to 4/6 HLA-mismatched DUOC-01; this mimics the typical worst-case clinical 
mismatch for CB transplants. In two experiments, proliferation of 4/6 mismatched CB 
MNCs was approximately twice as high as the proliferation of autologous CB MNCs (Table 
V, column C), 10- to 20-fold lower than the response of randomly matched PB MNCs [Table 
V].
We next explored whether allo-recognition of DUOC-01 by normal MNCs causes release of 
cytokines or if DUOC-01 releases cytokines in response to MNCs by measuring 
accumulation cytokines in MLC supernatants. Results of experiments with three 
manufacturing lots of DUOC-01 and various effector cell populations showed lot-to-lot 
variation, as discussed in detail in Supplementary Table I. However, consistent with the 
results of cytokine accumulation during the manufacture of DUOC-01 presented above, IL-4 
was not detected in any of the supernatants, and IL-10 accumulated in all cultures containing 
DUOC-01 whether or not other cell types were present.
Discussion
In this report, we describe a novel cell product, DUOC-01, manufactured from banked 
umbilical CB for use as an intrathecally delivered adjuvant cell therapy to treat the CNS in 
patients undergoing myeloablative unrelated donor CB transplantation for selected IMDs. 
Morphological, flow cytometric and immunohistochemical analyses of DUOC-01 all 
suggest that the cell product is composed predominantly of monocytic/macrophage lineage 
cells. As such, more than 95% of DUOC-01 cells express the hematopoietic lineage marker 
CD45, and >50% of the cells in DUOC-01 express the αM integrin CD11b. In addition, 
most or all of the cells expressed macrophage markers CD14, HLA-DR, CD16, CD206, 
CD163, Iba1 and iNOS. All the morphological types that we observed in cultures during 
manufacturing are similar to the variety of morphologies that have been described in 
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preparations of human macrophage, including brain macrophage and microglia [10–12]. 
DUOC-01 may also be related to donor microglial cells present in the brains of patients 
months after transplantation [3]. Ki67 and BrdU staining revealed that DUOC-01 cultures 
include many proliferative cells, which suggests that expansion of some subpopulation of 
CB cells occurs during manufacturing. The most straightforward hypotheses for the origin of 
the cells in DUOC-01 cultures are that they arise from hematopoietic myeloid progenitors or 
monocytes in the CB unit and differentiate into macrophage-like cells in culture. We are 
currently exploring this issue further. Because DUOC-01 cells are cultivated for 21 days in 
the presence of a variety of cytokines and are exposed to products of cells that die and are 
cleared during the manufacturing process, it is unlikely that cells in DUOC-01 are identical 
to any discrete population in CB.
Macrophage and microglia can become activated in different ways to express primarily pro- 
or anti-inflammatory activities. M1-type pro-inflammatory and M2-type anti-inflammatory 
cells are extremes of a functional continuum with many cells showing mixed expression of 
inflammatory and anti-inflammatory and regenerative activities [13,14]. The activities of 
such cells are particularly important in dealing with CNS inflammation [15–21]. Because 
neuro-inflammation characteristically contributes to the pathology of the IMDs that we are 
treating with DUOC-01, we explored whether DUOC-01 cells expressed markers 
characteristic of highly polarized M1 and M2 cells. We did not find a clear polarization in 
that the cells expressed iNOS and CD16 typically associated with M1 cells and CD163 and 
CD206, often associated with M2 cells.
We also measured production of cytokines by DUOC-01 cells as a potential indication of 
potential pro- or anti-inflammatory activities. The concentrations of the cytokines that 
accumulated in DUOC-01 supernatants during manufacturing reflect several parameters: 
synthesis and secretion, degradation in the culture medium and/or after re-uptake by cells, 
the number of cells in culture at the time of harvest and culture feeding schedules. Despite 
this complexity, IL-6 and IL-10 accumulated in physiologically significant amounts (7.4–
144 pmol/L and 0.48–21.2 pmol/L, respectively) in the supernatants of all lots of DUOC-01 
during the manufacturing process. TGF-β was detected at physiologically relevant 
concentrations (mean of approximately 40 pmol/L) in seven of eight batches. IL-6 and IL-10 
could also be detected in culture supernatants after DUOC-01 cells were harvested, washed 
and passaged into fresh tissue culture medium for 3 additional days. IL-10 also accumulated 
in MLC supernatants from cultures containing DUOC-01 cells. The production of both 
IL-10 and IL-6 by DUOC-01 could potentially provide beneficial anti-inflammatory and 
pro-angiogenic and pro-neurogenic effects in vivo.
Cells from DUOC-01 products responded to PMA and TNF-α by increasing secretion of 
cytokines. Secretion of IL-6 and of IL-10 was increased by both agents. IL-10 secretion was 
increased more strongly than IL-6. Both agents also stimulated accumulation of IL-1β. 
Secretion of other cytokines was weakly increased by these agents. IFN-γ strongly increased 
secretion of all the other cytokines in the panel, including both pro- and anti-inflammatory 
cytokines. Thus, DUOC-01 cells can respond differentially to inflammatory stimuli, but, 
again, IL-6 and IL-10 are primary products.
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Like the immunocytochemistry analyses, these cytokine data all suggest an intermediate 
type of polarization between M1 and M2 activities. Expression of IL-10 in all lots of 
DUOC-01 and of TGF-β in all but one lot is consistent with M2 type macrophage/microglial 
activities. Both of these cytokines can have anti-inflammatory properties and are capable of 
dampening pathological reactions caused by IL-1, TNF-α, IFN-γ and other pro-
inflammatory molecules [22,23]. The increase in accumulation of these cytokines after 
stimulation with TNF-α and INF-γ or with allogeneic MNCs is consistent with the idea that 
these cells could dampen an on-going inflammatory reaction. We found that the 
manufacturing process for DUOC-01 results in a cell population that has significantly more 
IL-10 transcripts than the CB cells used to initiate the cultures. Transcript levels for TNF-α, 
TGF-β and INF-γ transcripts did not change, again suggesting an important role for anti-
inflammatory IL-10 in DUOC-01 cells. However, DUOC-01 could respond to IFN-γ by 
producing inflammatory cytokines.
Expression of IL-6 by these cells also indicates a potentially more complex participation by 
DUOC-01 in on-going brain inflammatory states. IL-6 is a well-known pro-inflammatory 
mediator, and IL-6 has been cited as a potential contributor to the pathology of Krabbe 
disease and other IMDs [24–26]. However, IL-6 also has anti-inflammatory properties, with 
the pro- and anti-inflammatory effects of this molecule depending in part on whether it 
signals through soluble or membrane bound receptors [27]. The role of IL-6 in the brain is 
particularly diversified, and this cytokine can promote repair of brain damage in several 
different contexts [27–30]. In particular, it helps mediate remyelination of curpizone-induced 
lesions of the corpus collosum in mice [31]. We will present evidence elsewhere that 
DUOC-01 cells can promote remyelination in this model [32].
These results support the concept of using intrathecally administered DUOC-01 to deliver 
factors to the brain in the period before progenitors derived from the systemic CB transplant 
engraft the brain in sufficient numbers to exert therapeutic effects. As noted above, IL-10, 
TGF-β and possibly IL-6 could have additional beneficial effects in this clinical context. In 
addition, we found that DUOC-01, manufactured from normal donors, expresses normal 
levels of all 11 secreted lysosomal enzymes that we assayed. Transcript abundance for one 
of these, GALC, was increased more than 4-fold during the manufacture of DUOC-01. 
Thus, DUOC-01 could also provide wild-type enzyme to cross-correct IMD in the CNS 
shortly after administration. Biodistribution studies after intrathecal administration of 
DUOC-01 in newborn, immune-incompetent mice show that DUOC-01 is generally well 
tolerated and that some DUOC cells persist in the brain and spinal cord for at least 56 days 
[33]. Thus, these cells could in principle continue to produce therapeutic products for an 
extended period until permanent engraftment is established.
On the other hand, DUOC-01 cells express HLA-DR, and our MLC studies indicate that 
DUOC-01 can be recognized by alloreactive MNCs. The magnitude of the proliferative 
response of MNCs to DUOC-01 in MLCs depended on the degree of HLA mismatch 
between the cell product and the MNCs. MNCs that were 4/6 matches to DUOC-01 
proliferated very weakly if at all in MLC reactions, but randomly mismatched MNCs 
proliferated strongly.
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We have designed our clinical protocol to minimize the likelihood that either host-versus-
graft reactions such as those detected in the MLC studies or graft-versus-host disease 
(GVHD) could mitigate the potential benefits of DUOC-01. First, our flow cytometry and 
MLC studies demonstrate that alloreactive T cells die during manufacturing of DUOC-01. 
The DUOC-01 cell product will not be released for clinical use if it contains more than 5 × 
103 CD3+ T cells/kg of patient body weight. Second, we will administer DUOC-01 28 days 
after myeloablative conditioning and conventional CB transplant and only after donor cell 
engraftment without significant acute graft versus host disease is documented. At this time, 
the recipient immune system will still be ablated by pre-transplant chemotherapy, and no 
patient T cells will remain in circulation. Any donor T cells will be autologous to the 
DUOC-01 cells and therefore recognized as self. Thus, allo-rejection of DUOC-01 is 
unlikely to occur or to abrogate the potential beneficial effects of the product. When the 
patient’s immune system regains function many months later, T cells arising in the recipient 
from the donor CBU will be matched to DUOC-01 because DUOC-01 and the transplant 
donor are derived from the same CBU. Myeloablation and 9 to 12 months of post-transplant 
anti-GVHD immunosuppressive therapy will also mitigate against neuro-inflammation and 
rejection. Finally, DUOC-01 will not be administered if acute grade III or IV GVHD is 
present in the patient to minimize the chance that dysregulated immune response caused by 
GVHD could influence interactions between DUOC-01 and the recipient. This protocol will 
reduce the likelihood of HLA-mediated allogeneic reactions between DUOC-01 and the 
recipient’s newly formed immune system. Consequently, we believe that intrathecally 
administered DUOC-01 will be able to persist in the CNS compartment of myelo-ablated 
CB transplant patients and have the potential to deliver beneficial cytokines and enzyme as a 
bridging therapy before establishment of full, permanent engraftment in the brains of 
patients with IMD. A clinical trial (NCT02254863) that embodies the design outlined here 
has been initiated and is enrolling patients.
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Figure 1. 
Range of cell morphology in DUOC-01 cell product at time of harvest. Cultures included 
long, bipolar, phase-dense cells with radial processes (single broad arrow). Very large, flat, 
vesiculated cells (indicated by double broad arrows) as large as 285 μm in diameter were 
common. Highly refractive, small cells (thin arrow) were abundant. See text for description 
of designated cell types.
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Figure 2. 
DUOC products include proliferating cells. (A–C) Fluorescent images of DUOC stained 
with (A) Ki67 and (B) DAPI; (C) is an overlay of green Ki67 and blue DAPI signals. (D–F) 
Peroxidase/diaminobenzidase-linked BrdU staining of DUOC. (D and E) Dark brown nuclei 
that have incorporated BrdU. (F) Control cells not exposed to BrdU. Scale bar = 50 mm.
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Figure 3. 
Morphological changes of DUOC-01 cells during manufacturing. In each row, elapsed time 
from the image on the right is indicated and an arrow shows a single cell in different frames. 
(A, F, G) Spread-out cells rounding up to become a motile cell. (B, C) Cell shape changing 
from elongated to round. (D, E) Motile refractile cells attaching to become flat, spread-out 
cells. (H) A flat cell becoming an elongated, bipolar, motile cell.
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Figure 4. 
Flow cytometric analysis of DUOC-01. (A) Typical flow forward and side-scatter (FSC, 
SSC) and viability staining cytograms used to identify viable cells for analysis of marker 
expression. (B) Flow histogram of gated population in (A) stained with 7-amino-actinmycin 
(7AAD) (red line) and anti–glycophorin A (GlyA) to identify viable cells and erythrocytes, 
respectively. (C) Expression of CD11b and CD14 and (D) of CD3 and CD45 by cells in 
DUOC-01 product. Cells analyzed were gated as shown in (A) and (B). In all cases, 
fluorescence gates for antibody staining were set by use of cells exposed to appropriate 
isotype controls.
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Figure 5. 
Cells in DUOC-01 product express a variety of macrophage/microglial antigens. All images 
are prepared for immunocytochemistry with antibody to the antigen indicated and 
counterstained with DAPI. Immunostaining is red or green; DAPI, blue. All images are at 
same magnification. White scale bar in CD11b image is 50 μm.
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Table I
Percentage of cells expressing various antigens in multiple lots of DUOC-01.
CD3+ CD11b+ CD45+ CD14+
Average 0.00 69.9 86.8 40.0
SD 0.00 15.7 11.6 19.2
Samples of 17 DUOC-01 manufacturing runs were analyzed by means of multiparameter flow cytometry as described in Figure 2; n = 17.
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